118 related articles for article (PubMed ID: 12557434)
41. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
Kashiwabara K; Nakamura H; Kiguchi T; Yagyu H; Kishi K; Wei BR; Yoneyama K; Matsuoka K
Clin Chim Acta; 1997 Oct; 266(2):149-55. PubMed ID: 9437543
[TBL] [Abstract][Full Text] [Related]
42. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
43. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.
Holdenrieder S; Stieber P; von Pawel J; Raith H; Nagel D; Feldmann K; Seidel D
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5981-7. PubMed ID: 15447981
[TBL] [Abstract][Full Text] [Related]
44. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Lung Cancer; 2009 Jan; 63(1):128-35. PubMed ID: 18571761
[TBL] [Abstract][Full Text] [Related]
45. [Adjuvant chemotherapy in non-small cell lung cancer].
Taillade L; Soria JC; André F; Grunenwald D; Dunant A; Pignon JP; Le Chevalier T
Bull Cancer; 2004 Jan; 91(1):63-7. PubMed ID: 14975806
[TBL] [Abstract][Full Text] [Related]
46. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
47. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
[TBL] [Abstract][Full Text] [Related]
48. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
[TBL] [Abstract][Full Text] [Related]
49. [Postoperative adjuvant therapy for 189 patients with completely resected non-small cell lung cancer of stage III(A)].
Li Q; Gao JM; Liang PY; Xie FY; Liu GZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1463-6. PubMed ID: 15566658
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
Waller D; Peake MD; Stephens RJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG
Eur J Cardiothorac Surg; 2004 Jul; 26(1):173-82. PubMed ID: 15200998
[TBL] [Abstract][Full Text] [Related]
51. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
52. [Lung carcinomas with interstitial pneumonia; detection of lung cancers by CYFRA and selection of surgical procedure].
Takahashi N; Tsunematsu K; Suzuki A; Kaneda T
Kyobu Geka; 2005 Jan; 58(1):15-9. PubMed ID: 15678960
[TBL] [Abstract][Full Text] [Related]
53. Tumor markers as prognostic factors in treated non-small cell lung cancer.
Trapé J; Buxo J; Pérez de Olaguer J; Vidal C
Anticancer Res; 2003; 23(5b):4277-81. PubMed ID: 14666638
[TBL] [Abstract][Full Text] [Related]
54. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
Dunant A; Pignon JP; Le Chevalier T
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5017s-5021s. PubMed ID: 16000606
[TBL] [Abstract][Full Text] [Related]
56. Surgery after multimodality treatment for non-small-cell lung cancer.
Stamatis G; Eberhard W; Pöttgen C
Lung Cancer; 2004 Aug; 45 Suppl 2():S107-12. PubMed ID: 15552790
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
Dediu M; Horvat T; Tarlea A; Anghel R; Cordos I; Miron G; Iorga P; Alexandru A; Nistor C; Grozavu C; Savu C
Lung Cancer; 2005 Jan; 47(1):93-101. PubMed ID: 15603859
[TBL] [Abstract][Full Text] [Related]
58. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
[TBL] [Abstract][Full Text] [Related]
59. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
60. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
